MedEx answers any queries you might have regarding Valcyte-450 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Indications for taking of Valcyte.
Valcyte is intended for the treatment of cytomegalovirus (CMV) retinitis in patients with diagnosed AIDS, as well as to prevent the occurrence of CMV infection in patients who underwent surgery with organ transplantation.
Active components and method of application of Valcyte.
The active substance of Valcyte is valganciclovir hydrochloride. Due to the wide impact of the remedy on the body, it should be noted that valganciclovir hydrochloride dramatically suppresses the multiplication of herpes-group viruses and prevents their spread throughout the body. Ganciclovir (formed from valganciclovir hydrochloride), performs virostatic activity: suppresses the synthesis of the viral cell, inhibits the incorporation of deoxyguanosine into viral DNA, limits the elongation of viral DNA.
Valcyte is a remedy that belongs to the group of funds for the treatment of HIV infections and other antiviral agents. Valcyte has a fast mechanism of action on the body and is characterized by a high level of metabolism, so the effect of taking one pill appears with a minimum time interval.
Dosage of Valcyte
Due to the fact that the active substance Valcyte, when ingested quickly turns into ganciclovir, you must strictly follow the dosing regimen to prevent the occurrence of an overdose. The amount of the dose taken depends strictly on the diagnosis and the general condition of the patients, is determined exclusively by the attending physician individually for each patient. With maintenance therapy with inactive CMV retinitis, two tablets are recommended twice a day (900 mg per day). The same dosage is used for preventive measures after organ transplantation. When taking medication, it is necessary to monitor creatine levels, in order to avoid the occurrence of side effects.
Clinical trials of Valcyte.
During clinical trials, the high efficacy after taking Valcyte in patients diagnosed with AIDS was confirmed. So, after four weeks of treatment with the remedy under consideration, it was diagnosed that 46% of patients had a sharp decrease in the release of cytomegalovirus. It is also known that the incidence of CMS-retinitis in patients after organ transplantation was only 10% – this is a very impressive indicator, since there is a high level of acute organ rejection in the event of an infectious disease.